(Q38152646)

29 August 2017

Pharmacological agents for NASH. (English)

1 reference

29 August 2017

1 reference

Vlad Ratziu

1

1 reference

PubMed ID

24126564

29 August 2017

language of work or name

English

0 references

publication date

15 October 2013

1 reference

Nature Reviews Gastroenterology & Hepatology

29 August 2017

1 reference

29 August 2017

10

1 reference

29 August 2017

11

1 reference

29 August 2017

676-685

1 reference

https://scigraph.springernature.com/pub.10.1038/nrgastro.2013.193

29 August 2017

0 references

cites work

Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Endpoints and clinical trial design for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Induction of peroxisome proliferator-activated receptor gamma during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPbeta, C/EBPdelta, and glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

PPARgamma induces the insulin-dependent glucose transporter GLUT4 in the absence of C/EBPalpha during the conversion of 3T3 fibroblasts into adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Effects of pioglitazone on lipid and lipoprotein metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Effects of identical weight loss on body composition and features of insulin resistance in obese women with high and low liver fat content

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up st

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Vitamin E: an overview of major research directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Vitamin E mediates cell signaling and regulation of gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Vitamin E deficiency induces liver nuclear factor-kappaB DNA-binding activity and changes in related genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Tocotrienols: Vitamin E beyond tocopherols

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Vitamin E in human low-density lipoprotein. When and how this antioxidant becomes a pro-oxidant

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Prevention of tocopherol-mediated peroxidation in ubiquinol-10-free human low density lipoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Vitamins in human arteriosclerosis with emphasis on vitamin C and vitamin E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Effect of high-dose vs standard-dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Antioxidants as therapeutic agents for liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Vitamin intake and liver cancer risk: a report from two cohort studies in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Treatment of NASH with ursodeoxycholic acid: pro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Omega 3 - Omega 6: What is right for the liver?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Hepatic n-3 polyunsaturated fatty acid depletion promotes steatosis and insulin resistance in mice: genomic analysis of cellular targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Effect of α-linolenic acid on endoplasmic reticulum stress-mediated apoptosis of palmitic acid lipotoxicity in primary rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

n-3 fatty acids and cardiovascular events after myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

n-3 fatty acids in patients with multiple cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Effect of fish oil on arrhythmias and mortality: systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Fish intake, contaminants, and human health: evaluating the risks and the benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Antioxidant and radical scavenging properties of 8-oxo derivatives of xanthine drugs pentoxifylline and lisofylline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pentoxifylline decreases oxidized lipid products in nonalcoholic steatohepatitis: new evidence on the potential therapeutic mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Metformin reverses fatty liver disease in obese, leptin-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Metformin in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Nuclear receptors as new perspective for the management of liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Farnesoid X receptor is essential for normal glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Spontaneous development of liver tumors in the absence of the bile acid receptor farnesoid X receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Spontaneous hepatocarcinogenesis in farnesoid X receptor-null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

PPAR delta: a dagger in the heart of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Peroxisome proliferator-activated receptor-delta induces insulin-induced gene-1 and suppresses hepatic lipogenesis in obese diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Ligand activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) attenuates carbon tetrachloride hepatotoxicity by downregulating proinflammatory gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Role of peroxisome proliferator-activated receptor {delta}/{beta} in hepatic metabolic regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Paradoxical roles for lysyl oxidases in cancer--a prospect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Nutrients intake and the risk of hepatocellular carcinoma in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Subcutaneous vitamin E ameliorates liver injury in anin vivo model of steatocholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

A position statement on NAFLD/NASH based on the EASL 2009 special conference

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Transcriptional control of adipogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Values and limitations of serum aminotransferases in clinical trials of nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Is vitamin E beneficial in chronic liver disease?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Pharmacologic doses of vitamin E improve insulin action in healthy subjects and non-insulin-dependent diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Lower tocopherol serum levels in subjects with abdominal adiposity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Vitamin E reduces oxidant injury to mitochondria and the hepatotoxicity of taurochenodeoxycholic acid in the rat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Supplementation of Diets with α-Tocopherol Reduces Serum Concentrations of γ- and δ-Tocopherol in Humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Diet and hepatocellular carcinoma: a case-control study in Greece

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Omega-3 fatty acids and liver disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Consumption of n-3 fatty acids and fish reduces risk of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Carnitine metabolism and its regulation in microorganisms and mammals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: a histopathological follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Insulin sensitizers in nonalcoholic steatohepatitis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2013.193

Therapeutic benefit of PDE4 inhibitors in inflammatory diseases.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24126564

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24126564

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24126564

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2013.193

1 reference

29 August 2017

1 reference

PubMed ID

24126564